NCE Discovery

Poziotinib (pan-HER)

• Irreversible potent pan-HER inhibitor
• Effective and tolerable for Her-2 & EGFR driven cancers

Olita^®(olmutinib)

• Selective & excellent activity to EGFR mutants including T790M
• Clinical trial being conducted in advanced NSCLC patients with EGFR mutations
• May 2016. Accelerated approval granted by MFDS (Korean Brand name: Olita^® Tab.)

HM71224 (BTK)

• Irreversibly designed Bruton's tyrosine kinase (BTK) inhibitor
• Potent inhibition of BTK signaling in B cell such as p-BTK and p-PLCγ

HM95573 (RAF)

• Selective pan-RAF inhibitor
• Potentially targeting B-RAFmut and/or N-RASmut /C-RAF driven cancers